Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings Results

Syndax Pharmaceuticals (NASDAQ:SNDX) issued its quarterly earnings results on Tuesday. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.15, Briefing.com reports. The firm had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.16 million. During the same period last year, the firm earned ($0.73) EPS.

Syndax Pharmaceuticals Price Performance

Shares of SNDX opened at $21.52 on Friday. Syndax Pharmaceuticals has a 52 week low of $13.14 and a 52 week high of $25.34. The business’s 50 day moving average price is $19.09 and its 200-day moving average price is $20.33.

Wall Street Analyst Weigh In

Several research analysts have recently commented on SNDX shares. JPMorgan Chase & Co. decreased their price objective on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. StockNews.com upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. The Goldman Sachs Group boosted their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Thursday. Citigroup boosted their price target on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, Barclays boosted their price target on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a report on Thursday, August 15th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.82.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).